Enveric Biosciences Inc. (ENVB)
Enveric Biosciences Statistics
Share Statistics
Enveric Biosciences has 1.92M shares outstanding. The number of shares has increased by 39.43% in one year.
| Shares Outstanding | 1.92M |
| Shares Change (YoY) | 39.43% |
| Shares Change (QoQ) | 14.01% |
| Owned by Institutions (%) | 8.17% |
| Shares Floating | 1.6M |
| Failed to Deliver (FTD) Shares | 130.48K |
| FTD / Avg. Volume | 5.02% |
Short Selling Information
The latest short interest is 330.22K, so 3.18% of the outstanding shares have been sold short.
| Short Interest | 330.22K |
| Short % of Shares Out | 3.18% |
| Short % of Float | 3.48% |
| Short Ratio (days to cover) | 0.31 |
Valuation Ratios
The PE ratio is -2434.79 and the forward PE ratio is -0.2. Enveric Biosciences's PEG ratio is 66.44.
| PE Ratio | -2434.79 |
| Forward PE | -0.2 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 21.52 |
| P/FCF Ratio | -2.99 |
| PEG Ratio | 66.44 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Enveric Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.
| Current Ratio | 1.53 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -4435.93 |
Financial Efficiency
Return on equity (ROE) is -0.01% and return on capital (ROIC) is -842.19%.
| Return on Equity (ROE) | -0.01% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -842.19% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.47K |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 28.91K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -88.8% in the last 52 weeks. The beta is 0.19, so Enveric Biosciences's price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | -88.8% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 6.93 |
| Relative Strength Index (RSI) | 54.2 |
| Average Volume (20 Days) | 2.6M |
Income Statement
| Revenue | n/a |
| Gross Profit | -408.03K |
| Operating Income | -16.45M |
| Net Income | -17.29K |
| EBITDA | -16.85M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8.09 |
Balance Sheet
The company has 2.29M in cash and 0 in debt, giving a net cash position of 2.29M.
| Cash & Cash Equivalents | 2.29M |
| Total Debt | 0 |
| Net Cash | 2.29M |
| Retained Earnings | -96.5M |
| Total Assets | 4.79M |
| Working Capital | 3.5M |
Cash Flow
In the last 12 months, operating cash flow was -14.09M and capital expenditures -5.18K, giving a free cash flow of -14.1M.
| Operating Cash Flow | -14.09M |
| Capital Expenditures | -5.18K |
| Free Cash Flow | -14.1M |
| FCF Per Share | -6.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -289.96% |
| FCF Yield | -262.48% |
Analyst Forecast
Currently there are no analyst rating for ENVB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 29, 2025. It was a backward split with a ratio of 1:15.
| Last Split Date | Jan 29, 2025 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -31.88 |
| Piotroski F-Score | 3 |